The continuous evolution of Tides manufacturing excellence

Peptides and oligonucleotides (TIDES) are transforming modern medicine by precisely targeting disease pathways, expanding treatment options for chronic, metabolic, and rare conditions. As more therapies gain approval, global demand is surging – and the industry must scale without compromising safety, quality, or ustainability.
For contract development and manufacturing organizations (CDMOs), responding to demand requires more than simply upping capacity. Scaling production while maintaining quality, sustainability, and compliance requires a deliberate shift toward advanced manufacturing, embracing digitalization, and promoting continuous improvement.
Hans Van Hees, Chief Operations Officer at Bachem, discusses how the CDMO is adapting to these changes — providing stability, reliability, and leadership as the TIDES industry evolves.

Advanced manufacturing and scale-up: Looking beyond capacity
A defining feature of today’s TIDES market is the rise of GLP-1 and related peptides – a class of molecules driving demand and increasing manufacturing complexity. For Bachem, this has meant moving from a development-focused CDMO portfolio to a more production-driven Contract Manufacturing Organization (CMO).